New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
12:14 EDTUNH, QCOR, MNKUnitedHealth updates policy, says Acthar isn't medically necessary in MS
In an updated drug policy with an effective date of August 1, UnitedHealthcare (UNH) stated that it does not view Questcor's (QCOR) H.P. Acthar gel as medically necessary for treatment of acute exacerbations of multiple sclerosis. "Published clinical evidence does not demonstrate superiority of Acthar to other available corticosteroids," UnitedHealthcare stated in its bulletin. Note that Mallinckrodt (MNK) has proposed a merger with Questcor. UnitedHealthcare's website cites June 23 as the published date of the new drug policy for Acthar. Reference Link
News For QCOR;UNH;MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 15, 2015
09:31 EDTMNKAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 14, 2015
07:33 EDTUNHUnitedHealth would consider Optum spinoff if benefits erode, says UBS
Subscribe for More Information
May 11, 2015
07:40 EDTUNHFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
07:13 EDTUNHUnitedHealth management to meet with UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use